Rituximab in Auto-Immune Hemolytic Anemia

Warm Autoimmune Hemolytic Anemia Clinical Trial

— RAHIA  

Official title:

Rituximab in Adult's Warm Auto-Immune Hemolytic Anemia : a Phase III, Double-bind, Randomised Placebo-controlled Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01181154
• Other study ID #: P080704
• Secondary ID: 2008-008255-42
• Status: Completed
• Phase: Phase 3
• First received: August 12, 2010
• Last updated: October 18, 2017
• Start date: March 3, 2011
• Est. completion date: January 8, 2016

Study information

• Verified date: October 2017
• Source: Assistance Publique - Hôpitaux de Paris
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The hypothesis based on retrospective data is that, the rate of overall response-rate (PR + CR) at 1 year will be much higher in the rituximab arm (80%) than in the placebo arm (20%).Thirty four patients (17 in each arm) will be include (amendment n°6 - 15/10/2013) over a 3 year period (amendment n°3 - 11/12/2012).

Description:

The primary aim of the study is to assess the efficacy (overall response rate at 1 year) of rituximab (an anti-CD20 monoclonal antibody) in AIHA due to warm autoantibody when administered at the initial phase of the disease. All eligible patents with a newly diagnosed AIHA (within 6 weeks after diagnosis) will be treated by corticosteroids at standard dose (prednisone 1 mg/kg/day) and will be randomized into 2 arms: Rituximab or placebo 1000 mg on days 1 and 15 in a 1/1 ratio. As soon as at least a partial remission (PR) of AIHA will be achieved, the daily dose of prednisone will be tapered following the rules provided by the protocol.

The hypothesis based on retrospective data is that, the rate of overall response-rate (PR + CR) at 1 year will be much higher in the rituximab arm (80%) than in the placebo arm (20%).Thirty four patients (17 in each arm) will be include (amendment n°6 - 15/10/2013) over a 3 year period (amendment n°3 - 11/12/2012).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 32
• Est. completion date: January 8, 2016
• Est. primary completion date: January 8, 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age > 18 years

2. AIHA defined at time of diagnosis by a Hgb level £ 10 g/dL, with a reticulocytes count > 120 109/L, signs of hemolysis (at least a haptoglobin level < 4 mg/L), and a positive direct antiglobulin test (DAT) ( IgG or IgG + complement pattern).

3. Disease duration equal or less than 6 weeks at time of inclusion --> removed by amendment n°4 and substituted by :First episode of AIHA to "hot" antibody previously untreated or treated corticosteroids for less than 6 weeks.

4. Patients with an associated autoimmune thrombocytopenia (Evans' syndrome) will be eligible for the study if the platelet count is over 30 x 109/L at inclusion.

5. Normal level gammaglobulins in the serum (i.e. >5g/L) at inclusion.

6. Absence of detectable lymph nodes on a total body CT-scan (to be performed before inclusion if not performed at diagnosis).

7. Effective means of contraception during treatment and for six months after completion of treatment for all women of child bearing age

8. Negative serum pregnancy test within 14 days prior to study entry.

9. Written informed consent

Exclusion Criteria:

Previous treatment with rituximab

1. AIHA diagnosed and treated more than 6 weeks prior to inclusion removed by amendment n°4 and substituted by AIHA relapsed or newly diagnosed but treated with corticosteroids for more than 6 weeks

2. Ongoing immunosuppressive therapy (other than corticosteroids) or previous treatment administered within 2 weeks prior to the beginning of the study treatment

3. Non-Hodgkin Lymphoma (NHL) other than stage A chronic lymphoid leukemia

4. Previous or concomitant malignancy other than basal cell or squamous cell carcinoma of the skin, carcinoma-in-situ of the cervix, or other malignancy for which the patient had not been disease-free for at least 5 years.

5. Autoimmune disorder such as SLE with at least one extra-hematological manifestation requiring a treatment with steroids and/or immunosuppressive drugs.

6. Any other associated cause congenital or acquired hemolytic anemia (except thalassemia trait or heterozygous sickle cell anemia).

7. Negative DAT or DAT positive with isolated anti-C3d pattern related to the presence of a monoclonal IgM with cold agglutinin properties.

8. Positive HIV test and/or hepatitis virus C infection and/or positive hepatitis B virus surface antigen (HbsAg).

9. Neutrophils count < 1,000/mm 3 at inclusion.

10. Impaired renal function as indicated by a serum creatinine level > 2 mg/d

11. Inadequate liver function as indicated by a total bilirubin level > 2.0 mg/dL and/or an AST or ALT level > 2x upper limit of normal.

12. New York Heart Classification III or IV heart disease.

13. Previous history of severe psychiatric disorder or are unable to comply with study and follow-up procedures

14. Pregnant or lactating women, or woman planning to become pregnant within 12 months of receiving study drug

15. Absence of written informed consent.

Related Conditions & MeSH terms

• Anemia
• Anemia, Hemolytic
• Anemia, Hemolytic, Autoimmune
• Hemolysis
• Warm Autoimmune Hemolytic Anemia

Intervention

Drug:
• rituximab (Mabthera®)
1000 mg at day 1 and day 15
• Placebo
equivalent volume total

Locations

Country	Name	City	State
France	Henri Mondor University Hospital	Créteil

Sponsors (2)

Lead Sponsor	Collaborator
Assistance Publique - Hôpitaux de Paris	Hoffmann-La Roche

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall response rate (complete and partial response) in both arms		at 1 year
Secondary	Comparison in both arms of the mean cumulative doses of prednisone		at 1 year
Secondary	Comparison in both arms of the number of transfusions of packed red blood cells in both arms		at 1 year
Secondary	Comparison in both arms of the number of days in hospital		within the first year of follow-up
Secondary	Comparison in both arms of the number of patients requiring a splenectomy and/or an immunosuppressor		during the first 12 months of follow-up
Secondary	Comparison in both arm of the mortality		at 1 year
Secondary	Comparison in both arm of overall response (CR + PR)		at 2 years
Secondary	Comparison of the incidence of serious side effects in both arms		at 1 year